Federal Circuit keeps 180 days’ exclusion time in patent dance
The Federal Circuit has provided some guidance on the issue of 180 days’ notice of launch in a recent biosimilars ruling, in Amgen v Apotex, but practitioners say there will be a lot more litigation before the patent dance is fully clarified
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
